News & Media

Take a look inside our world

Press Releases

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Signi...

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significan

Teva Launches New “Pivot to Growth” Strategy

Teva Launches New “Pivot to Growth” Strategy

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now...

AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Avai

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding...

Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Seve

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

U.S. Mental Health Access Program Expands Medicine Donation to Seven New States

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspens...

Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension,

Teva to Launch New Growth Strategy at Investor Day

Teva to Launch New Growth Strategy at Investor Day

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10,...

Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

Complete Response Letter Received for AVT02 Biologics License Application

Complete Response Letter Received for AVT02 Biologics License Application
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Leslie McGibbon

Europe

Leslie.Mcgibbon@Tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Our People Working at Teva Patient Focus Social Impact Environment Leadership Quality ESG Generic Medicines Research and Development Diversity and inclusion Biopharm Global Operations Wellbeing Medicine Safety Teva api Innovation R&D Health & Technology

Celebrating Pride, Creating Connections

Celebrating Pride, Creating Connections

Getting Medicines to All Who Need Them

Getting Medicines to All Who Need Them

Protecting Our Planet

Protecting Our Planet

Teva’s 2022 Impact: A Closer Look

Teva’s 2022 Impact: A Closer Look

Doing Business the Right Way

Doing Business the Right Way

Maintaining a Responsible and Sustainable Supply Chain

Maintaining a Responsible and Sustainable Supply Chain

"What Took Us Years Could Now Take Half the Time": Innovation Is Redefining Pharma

"What Took Us Years Could Now Take Half the Time": Innovation Is Redefining Pharma

New R&D Facility in Hungary will Double Annual Testing Capability

New R&D Facility in Hungary will Double Annual Testing Capability

Erick Tyssier: 3 Trends I’m Watching

Erick Tyssier: 3 Trends I’m Watching

“We All Deserve to Feel Like We Belong”

“We All Deserve to Feel Like We Belong”
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more